New Jersey § 26:2l-4

§ 26:2l-4.

a. There is hereby established in the State Department of Health, the controlled dangerous

substances therapeutic research program. The program shall be limited to therapeutic research programs presently conducted

by the Bureau of Drugs in the Food and Drug Administration of the U.S. Department

of Health and Human Services or its successor and shall be administered by the commissioner

who shall promulgate rules and regulations necessary for the administration of this

act, including but not limited to rules and regulations which may be necessary to

require patients desiring certification pursuant to section 5 of this act 1 to release their medical records for the purposes of certification and follow-up

reports. In making such promulgations, the commissioner shall take into consideration all

Federal controlled dangerous substances laws and rules adopted pursuant to such laws. b. The program shall be limited to patients who are certified to the board, established

by section 5 of this act, by a practitioner as being involved in a life-threatening

or sense-threatening situation and who are not responding to drugs or where the drugs

administered have proven to be effective but where the patient has incurred severe

side effects. c. The names and medical records of individual patients who have either requested

certification or have been certified pursuant to section 5 of this act shall not be

released in any form which identifies the individual, except that the names and records

of such individuals shall be made available upon request for use in the enforcement

of laws regarding controlled dangerous substances (P.L.1970, c. 226; C. 24:21-1 et seq. ). 1

N.J.S.A. § 26:2L-5.